Re: Report Of Exempt Distribution.

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

fuzzyjr

Rank: Vice President [?]

Points: 4833 [?]

Votes: 36 Score: 3.1 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Report Of Exempt Distribution.

in response to

Re: Report Of Exempt Distribution.

KOO-KOO2

posted on Apr 17, 2024 05:45PM

"The saga continues"...... Yes, for Resverlogox.

Zenith on the other hand is doing just fine,..... IMO"

Hard to say , they've had no success according to you. Time will tell with both.

1 Recommendations

Reply New Message

Prev Message Back To Forum Threaded View Next Message

Please to post a reply